20th May 2016 06:29
LONDON (Alliance News) - Respiratory drugs company Vectura Group PLC on Friday said it expects to complete its merger with smaller peer Skyepharma PLC in June following the competition clearance the deal received earlier this week.
On Monday, the UK's Competition & Markets Authority confirmed the proposed merger does not qualify for investigation under investigation under the Enterprise Act 2002. The pair agreed an all-share merger in March.
Vectura now expects Skyepharma shares to be cancelled on June 9, and for the deal to complete the following day.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.